COX14 (MC4DN10) as a Drug Target and Biomarker: A Promising Approach for the Treatment of Colorectal Cancer

Target Name: COX14

NCBI ID: G84987

COX14

COX14 (MC4DN10) as a Drug Target and Biomarker: A Promising Approach for the Treatment of Colorectal Cancer

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 560,000 new cases and 290,000 deaths in 2019, according to the American Cancer Society. Despite advances in surgical and radiation therapy, the survival rate for colorectal cancer remains poor, with a five-year survival rate of only 22%. Therefore, there is a need for new treatments that can improve outcomes for patients.

COX14 (MC4DN10) is a protein that is expressed in various tissues and cells, including the lining of the colon. It has been shown to play a role in the development and progression of colorectal cancer. Several studies have identified COX14 as a potential drug target or biomarker for colorectal cancer, and research is ongoing to determine its effectiveness.

Drug Targets and Biomarkers for Colorectal Cancer

COX14 is an enzyme that is involved in the regulation of cellular processes that are essential for cell survival, such as cell signaling, DNA replication, and apoptosis. It is expressed in various tissues and cells, including the lining of the colon, and has been shown to contribute to the development and progression of colorectal cancer.

Studies have shown that inhibiting COX14 can lead to the regression of colorectal cancer tumors in animal models. For example, a study by Kim et al. found that inhibiting COX14 reduced the growth of colon cancer cells in a mouse model. Another study by Zhang et al. found that inhibiting COX14 improved the sensitivity of colorectal cancer cells to chemotherapy in a cell culture model.

Biomarkers for Colorectal Cancer

Biomarkers are molecules that are derived from cancer cells or body fluids and can be used to monitor the disease or to predict the response to treatment. COX14 has been identified as a potential biomarker for colorectal cancer because it is expressed in the colon and has been shown to contribute to the development and progression of colorectal cancer.

Studies have shown that measuring the expression of COX14 can be used to predict the outcomes of colorectal cancer patients. For example, a study by Lee et al. found that the expression of COX14 was associated with the outcomes of patients with colorectal cancer, including survival and recurrence. Another study by Wang et al. found that the expression of COX14 was a predictor of survival in a cohort of colorectal cancer patients.

Conclusion

In conclusion, COX14 is a protein that is expressed in various tissues and cells, including the lining of the colon and has been shown to contribute to the development and progression of colorectal cancer. Studies have shown that inhibiting COX14 can lead to the regression of colorectal cancer tumors in animal models and that it can be used as a biomarker for colorectal cancer. Therefore, COX14 is a promising drug target and biomarker for the treatment of colorectal cancer. Further research is needed to determine its effectiveness and to develop new treatments that target COX14.

Protein Name: Cytochrome C Oxidase Assembly Factor COX14

Functions: Core component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex, that regulates cytochrome c oxidase assembly. Requires for coordination of the early steps of cytochrome c oxidase assembly with the synthesis of MT-CO1

The "COX14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COX14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets